Advertisement

Topics

Top five promising drugs Phase III (November 2013)

16:52 EDT 24th June 2018 | BioPortfolio

THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS

DRUG DISEASE COMPANY
BMN-673 BRCA-mutation-positive breast cancer Biomarin Pharmaceuticals
eravacycline Complicated intra-abdominal infection Tetraphase Pharmaceuticals
ACAM-CDIFF™ Clostridium difficile infection Sanofi
Fovista™ Wet age-related macular degeneration Ophthotech
REG-1 Thrombosis in percutaneous coronary intervention Regardo Biosciences

 

 

 

 

 

Source: Thomson Reuters Cortellis Competitive Intelligence.

  
  
 
  
  
 

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top five promising drugs Phase III (November 2013) market research data and corporate reports here